[{"orgOrder":0,"company":"BioPharmX","sponsor":"Timber Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"Isotretinoin","moa":"RAR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BioPharmX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Topical","sponsorNew":"BioPharmX \/ BioPharmX","highestDevelopmentStatusID":"8","companyTruncated":"BioPharmX \/ BioPharmX"}]

Find Clinical Drug Pipeline Developments & Deals by BioPharmX

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The combined company will have a robust pipeline including Timber's two Phase 2b programs and a preclinical program targeting multiple niche orphan indications with no approved treatments as well as BioPharmX's two Phase 3-ready topical minocycline progr...

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 18, 2020

                          Lead Product(s) : Isotretinoin

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II

                          Recipient : Timber Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank